# US 2014/0348788 A1 · Method to modulate pigmentation process in the melanocytes of skin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0348788 A1
- Document ID: US20140348788A1
- Status: Published application
- Kind: A1
- Application number: 14/117,519
- Filed: 2012-05-16
- Published: 2014-11-27
- Earliest claimed: 2011-05-16
- Assignees: Council of Scientific and Industrial Research
- Inventors: Rajesh Sudhir Gokhale; Vivek Tirunelveli Natarajan; Parul Ganju
- Web page: https://patentgrep.com/patent/US20140348788A1

## CPC

- A61K 38/217: {IFN-gamma}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 31/08: for leprosy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention describes a method to modulate melanosome maturation process in melanocytes. Further, it describes a method to reversibly alter the process of pigmentation in the human epidermal skin. The method targets melanosome maturation and its transfer to keratinocytes, which are key processes involved in the pigmentation for its potential use in predictable and controlled regulation of pigmentation in human skin.

## Claims

### Claim 1

A method to reversibly alter melanosome maturation occurring in stage I and II in an epidermal melanocytes in a subject by contacting or withdrawing IFN-γ and its derivative, mimic, antagonist thereof with said melanocytes in a controlled manner,
and wherein the IFN-γ and derivative, mimic, antagonist thereof modulate the expression of IFN-γ pathway components selected from a group comprising IFNGR1, JAK1 and STAT1.

### Claim 2 (depends on 1)

The method as claimed in claim 1 wherein IFN-γ, or its derivative, or its mimic, or an antagonist, or components of IFN-γ pathway are contacted with melanocytes in the range of 100-500 U/ml for a period in the range of 1 to 10 days.

### Claim 3 (depends on 1)

The method as claimed in claim 1 wherein IFN-γ or its derivative, or a mimic or an antagonist of IFN-γ reversibly alters the levels of TYR, and TYRP2/DCT, CNO, HPS4, GPR143, OCA2, SLC7A11 and MCOLN3.

### Claim 4 (depends on 1)

The method as claimed in claim 1 wherein the transfer of melanosome to keratinocytes is altered by targeting components of IFN-γ pathway selected from the group comprising of IFNG, IFNGR1, JAK1 and STAT1.

### Claim 5

Use of IFN-γ and its components and its agonists and antagonists in modulating pigmentation in humans for clinical or cosmaceutical purposes.

### Claim 6

A method of treating skin pigmentation by administering to a subject IFN-γ or its derivative, or a mimic or antagonist of IFN-γ.

### Claim 7 (depends on 6)

The method as claimed in claim 6 wherein IFN-γ or its derivative, or a mimic or an antagonist of IFN-γ is administered to the subject by topical delivery or by sub-cutaneous delivery.

### Claim 8 (depends on 7)

The method as claimed in claim 7 wherein the topical delivery or sub-cutaneous delivery is in a dosage form selected from the group comprising, a powder, a solution, an emulsion, a fluid emulsion, a suspension, a fluid suspension, a semi-solid, an ointment, a paste, a cream, a gel, a jelly, a foam, an implant, an injection, a patch and a spray.

### Claim 9 (depends on 6)

The method as claimed in claim 6 useful for treating skin disorders selected from the group comprising of hyperpigmentation, hypopigmentation, uneven pigmentation, post inflammatory pigmentation, sun-damaged skin, pigmented birthmark, acanthosis nigricans and solar lentiges, age-related pigmentation changes, indeterminate leprosy, tuberculoid leprosy, borderline leprosy, leprematous leprosy.